155 related articles for article (PubMed ID: 11115587)
1. Splice variant expression of CD44 in patients with breast and ovarian cancer.
Sanchez Lockhart M; Hajos SE; Basilio FM; Mongini C; Alvarez E
Oncol Rep; 2001; 8(1):145-51. PubMed ID: 11115587
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
Stimpfl M; Tong D; Fasching B; Schuster E; Obermair A; Leodolter S; Zeillinger R
Clin Cancer Res; 2002 Jul; 8(7):2253-9. PubMed ID: 12114428
[TBL] [Abstract][Full Text] [Related]
3. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
4. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
Fichtner I; Dehmel A; Naundorf H; Finke LH
Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.
Terpe HJ; Störkel S; Zimmer U; Anquez V; Fischer C; Pantel K; Günthert U
Am J Pathol; 1996 Feb; 148(2):453-63. PubMed ID: 8579108
[TBL] [Abstract][Full Text] [Related]
7. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer.
Huang CS; Shen CY; Wang HW; Wu PE; Cheng CW
Clin Chim Acta; 2007 Sep; 384(1-2):69-74. PubMed ID: 17651715
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 isoforms in human breast carcinoma xenografts is not influenced by the treatment of mice with cytostatics or (anti-)hormones.
Dehmel A; Becker M; Lemm M; Fichtner I
Anticancer Res; 1999; 19(3A):1977-87. PubMed ID: 10470143
[TBL] [Abstract][Full Text] [Related]
10. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
Reeder JA; Gotley DC; Walsh MD; Fawcett J; Antalis TM
Cancer Res; 1998 Aug; 58(16):3719-26. PubMed ID: 9721884
[TBL] [Abstract][Full Text] [Related]
11. Loss of alternately spliced messenger RNA of the luteinizing hormone receptor and stability of the follicle-stimulating hormone receptor messenger RNA in granulosa cell tumors of the human ovary.
Reinholz MM; Zschunke MA; Roche PC
Gynecol Oncol; 2000 Nov; 79(2):264-71. PubMed ID: 11063655
[TBL] [Abstract][Full Text] [Related]
12. Comparison of telomerase and CD44 expression as diagnostic tumor markers in lesions of the thyroid.
Aogi K; Kitahara K; Urquidi V; Tarin D; Goodison S
Clin Cancer Res; 1999 Oct; 5(10):2790-7. PubMed ID: 10537343
[TBL] [Abstract][Full Text] [Related]
13. Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer.
Stickeler E; Möbus VJ; Kieback DG; Kohlberger P; Runnebaum IB; Kreienberg R
Anticancer Res; 1997; 17(6D):4395-8. PubMed ID: 9494539
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
Li BJ; Wang JY; Wang HY; Huang XP; Zhang LJ; Long H; Yang MT; Rong TH
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):766-9. PubMed ID: 17366790
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
Schmid BC; Rudas M; Fabjani G; Speiser P; Kaserer K; Leodolter S; Zeillinger R
Oncol Rep; 2003; 10(6):1981-5. PubMed ID: 14534730
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines.
Stickeler E; Runnebaum IB; Möbus VJ; Kieback DG; Kreienberg R
Anticancer Res; 1997; 17(3C):1871-6. PubMed ID: 9216637
[TBL] [Abstract][Full Text] [Related]
17. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
18. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
19. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck.
Boldrup L; Coates PJ; Gu X; Nylander K
J Pathol; 2007 Dec; 213(4):384-91. PubMed ID: 17935121
[TBL] [Abstract][Full Text] [Related]
20. Novel CD44 messenger RNA isoforms in human thyroid and breast tissues feature unusual sequence rearrangements.
Ermak G; Jennings T; Boguniewicz A; Figge J
Clin Cancer Res; 1996 Aug; 2(8):1251-4. PubMed ID: 9816294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
